Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein

Rodríguez-Nogales, Carlos; Garbayo, Elisa; Martínez-Valbuena, Iván; Sebastián, Víctor; Luquin, M. R.; Blanco-Prieto, María J.

doi:10.1016/j.ijpharm.2016.06.044

Cited by 14 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concentrations of 50, 100 and 200 µg mL −1 of Tl -SN showed a statistically similar cell proliferation relative to cells growing in DMEM expansion medium (control) and comparable values to those exposed to same concentrations of Bm -SFN, previously reported as good candidates for drug delivery or functionalization by diverse compounds with anti-inflammatory, anti-oxidant or anti-tumour properties, among others 29 , 32 , 34 , 43 , 44 . These Tl -SN results, together with those obtained from Tl- S films indicate a good cytocompatibility and no-cytotoxicity of the Tl -S.…”

Section: Resultssupporting

confidence: 56%

The silk of gorse spider mite Tetranychus lintearius represents a novel natural source of nanoparticles and biomaterials

Lozano-Pérez¹,

Pagán²,

Zhurov

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Spider mites constitute an assemblage of well-known pests in agriculture, but are less known for their ability to spin silk of nanoscale diameters and high Young’s moduli. Here, we characterize silk of the gorse spider mite Tetranychus lintearius, which produces copious amounts of silk with nano-dimensions. We determined biophysical characteristics of the silk fibres and manufactured nanoparticles and biofilm derived from native silk. We determined silk structure using attenuated total reflectance Fourier transform infrared spectroscopy, and characterized silk nanoparticles using field emission scanning electron microscopy. Comparative studies using T. lintearius and silkworm silk nanoparticles and biofilm demonstrated that spider mite silk supports mammalian cell growth in vitro and that fluorescently labelled nanoparticles can enter cell cytoplasm. The potential for cytocompatibility demonstrated by this study, together with the prospect of recombinant silk production, opens a new avenue for biomedical application of this little-known silk.

show abstract

Section: Resultssupporting

confidence: 56%

The silk of gorse spider mite Tetranychus lintearius represents a novel natural source of nanoparticles and biomaterials

Lozano-Pérez¹,

Pagán²,

Zhurov

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…TEM-based average size was only slightly greater (390 ± 88 nm) than that measured by the DLS method. It is worth emphasizing the similarity of these NPs with other PLGA NPs prepared according to other conventional elaboration methods [26][27][28].…”

Section: Discussionmentioning

confidence: 84%

“…The NPs Zeta potential was negative either with (-−16.9 ± 0.1 mV) or without (-−16.7 ± 0.2 mV) encapsulated enzyme, and its values agree with those reported in other studies for PLGA NPs (Panyam et aland Labhasetwar 20023). For instance, Rodriguez-Nogales et al [26] reported a practically coincident Zeta potential for PLGA NPs (-−16 ± 2 mV), which was ascribed to the acid functional groups of the copolymer in NPs polymer matrix.…”

Section: Discussionmentioning

confidence: 99%

Poly (lactic-co-glycolic acid) nanospheres allow for high l-asparaginase encapsulation yield and activity

Brito

Pessoa

Converti

et al. 2019

Materials Science and Engineering: C

View full text Add to dashboard Cite

The enzyme L-asparaginase (ASNase) is a key chemotherapeutic agent for the treatment of acute lymphoblastic leukemia (ALL) and other hematopoietic malignancies [1]. ASNase is an amidohydrolase belonging to the Nterminal nucleophile family, which requires autocleavage between Gly167 and Thr168 to become catalytically competent. This behavior differentiates it from other similar enzymes, in which the serine residue acts as the primary nucleophile. The enzyme produced by Escherichia coli is a homotetramer with a molecular weight of about 142 kDa [2]. Its catalytic action leads to asparagine (Asn) deamidation, resulting in the formation of aspartate (Asp) and ammonia as a by-product [3]. Since leukemic cells are auxotrophic for Asn [4], a reduction in the blood concentration of this amino acid resulting from ASNase action is an effective therapy for ALL, because under these conditions the cell cycle arrests in the G1 phase leading to apoptosis [5]. However, immunogenic reactions and pharmacokinetic limitations are responsible for early clearance of ASNase from blood plasma, i.e. for a short half-life [6]. To reduce these problems, new biotechnological alternatives for Poly (lactic-co-glycolic acid) nanospheres allow for high L-asparaginase encapsulation yield and activity

show abstract

“…Given the colocalization of α-syn with the lysosomal marker cathepsin D, the immunized mice could activate degradation pathways and thus eliminate α-syn more efficiently [203]. Following this study, another vaccination approach fused α-syn epitopes (α-syn [85][86][87][88][89][90][91][92][93][94][95][96][97][98][99] , α-syn [109][110][111][112][113][114][115][116][117][118][119][120][121][122][123][124][125][126] , α-syn [126][127][128][129][130][131][132][133][134][135][136][137][138][139]…”

Section: Active Immunizationmentioning

confidence: 99%

“…The modulation of PLK2-mediated phosphorylation was obtained by its inhibition with selective and brain-permeable chemical compound BI2536 [121,122]. In WT mice and rats, treatment with BI2536 inhibited pS129 α-syn [121,124], and could be delivered locally by nanoparticles [125] but the exact consequences on this inhibition on the pathology of PD are still to be decrypted. However, as kinases phosphorylating α-syn have ubiquitous distribution and possibly compensatory effects, the development of safe and efficient brain-penetrant compounds selectively modulating this PTM is extremely challenging.…”

Section: Phosphorylationmentioning

confidence: 99%

Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts

et al. 2020

View full text Add to dashboard Cite

Parkinson’s Disease (PD) is characterized both by the loss of dopaminergic neurons in the substantia nigra and the presence of cytoplasmic inclusions called Lewy Bodies. These Lewy Bodies contain the aggregated α-synuclein (α-syn) protein, which has been shown to be able to propagate from cell to cell and throughout different regions in the brain. Due to its central role in the pathology and the lack of a curative treatment for PD, an increasing number of studies have aimed at targeting this protein for therapeutics. Here, we reviewed and discussed the many different approaches that have been studied to inhibit α-syn accumulation via direct and indirect targeting. These analyses have led to the generation of multiple clinical trials that are either completed or currently active. These clinical trials and the current preclinical studies must still face obstacles ahead, but give hope of finding a therapy for PD with time.

show abstract

Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein

Cited by 14 publications

References 37 publications

The silk of gorse spider mite Tetranychus lintearius represents a novel natural source of nanoparticles and biomaterials

The silk of gorse spider mite Tetranychus lintearius represents a novel natural source of nanoparticles and biomaterials

Poly (lactic-co-glycolic acid) nanospheres allow for high l-asparaginase encapsulation yield and activity

Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts

Contact Info

Product

Resources

About